Literature DB >> 29478171

Interferon-α Silencing by Small Interference RNA Increases Adenovirus Transduction and Transgene Expression in Huh7 Cells.

Ana Alondra Sobrevilla-Navarro1, Ana Sandoval-Rodríguez1, Jesús Javier García-Bañuelos1, Juan Armendariz-Borunda1,2, Adriana María Salazar-Montes3.   

Abstract

Adenoviruses are the most common vectors used in clinical trials of gene therapy. In 2017, 21.2% of clinical trials used rAds as vectors. Systemic administration of rAds results in high tropism in the liver. Interferon types α and β are the major antiviral cytokines which orchestrate the host's immune response against rAd, limiting therapeutic gene expression and preventing subsequent vector administration. siRNA is small double-strand RNAs that temporally inhibit the expression of a specific gene. The aim is to evaluate the effect of IFN-α blocking by a specific siRNA on Ad-GFP transduction and on transgene expression in Huh7 cells in culture. Huh7 cells were cultured in DMEM and transfected with 70 nM of siRNA-IFN-α. Six hours later, the cells were exposed to 1 × 109 vp/ml of rAd-GFP for 24 h. Expression of IFN-α, TNF-α and the PKR gene was determined by RT-qPCR. Percentage of transduction was analyzed by flow cytometry and by qPCR. GFP expression was determined by western blot. 70 nM of siRNA-IFN-α inhibited 96% of IFN-α and 65% of TNF-α gene expression compared to an irrelevant siRNA. Percentage of transduction and transgene expression increased in these cells compared to an irrelevant siRNA. Inhibition of IFN-α expression by siRNA-IFN-α enabled a higher level of transduction and transgene expression GFP, highlighting the role of IFN-α in the elimination of adenovirus in transduced cells and thus suggesting that its inhibition could be an important strategy for gene therapy in clinical trials using adenovirus as a vector directed to liver diseases.

Entities:  

Keywords:  Adenovirus; Gene therapy; IFN-α; Innate immunity; siRNA

Mesh:

Substances:

Year:  2018        PMID: 29478171     DOI: 10.1007/s12033-018-0066-7

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  25 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

Review 2.  Viruses and interferon: a fight for supremacy.

Authors:  Michael G Katze; Yupeng He; Michael Gale
Journal:  Nat Rev Immunol       Date:  2002-09       Impact factor: 53.106

3.  Adenovirus infection triggers a rapid, MyD88-regulated transcriptome response critical to acute-phase and adaptive immune responses in vivo.

Authors:  Zachary C Hartman; Anne Kiang; Ruth S Everett; Delila Serra; Xiao Y Yang; Timothy M Clay; Andrea Amalfitano
Journal:  J Virol       Date:  2006-11-22       Impact factor: 5.103

4.  Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways.

Authors:  Jiangao Zhu; Xiaopei Huang; Yiping Yang
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

5.  Sensing infection by adenovirus: Toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator.

Authors:  Marcelo Nociari; Oksana Ocheretina; John W Schoggins; Erik Falck-Pedersen
Journal:  J Virol       Date:  2007-01-24       Impact factor: 5.103

Review 6.  Gene therapy clinical trials worldwide to 2007--an update.

Authors:  Michael L Edelstein; Mohammad R Abedi; Jo Wixon
Journal:  J Gene Med       Date:  2007-10       Impact factor: 4.565

Review 7.  Adenoviruses: update on structure and function.

Authors:  W C Russell
Journal:  J Gen Virol       Date:  2009-01       Impact factor: 3.891

8.  Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism.

Authors:  V N Krasnykh; G V Mikheeva; J T Douglas; D T Curiel
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

9.  Cirrhotic rat livers with extensive fibrosis can be safely transduced with clinical-grade adenoviral vectors. Evidence of cirrhosis reversion.

Authors:  J Garcia-Bañuelos; F Siller-Lopez; A Miranda; L K Aguilar; E Aguilar-Cordova; J Armendariz-Borunda
Journal:  Gene Ther       Date:  2002-01       Impact factor: 5.250

10.  Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy.

Authors:  S Salgado; J Garcia; J Vera; F Siller; M Bueno; A Miranda; A Segura; G Grijalva; J Segura; H Orozco; R Hernandez-Pando; M Fafutis; L K Aguilar; E Aguilar-Cordova; J Armendariz-Borunda
Journal:  Mol Ther       Date:  2000-12       Impact factor: 11.454

View more
  1 in total

1.  Delivery of Anti-IFNAR1 shRNA to Hepatic Cells Decreases IFNAR1 Gene Expression and Improves Adenoviral Transduction and Transgene Expression.

Authors:  J Guerrero-Rodríguez; A Cárdenas-Vargas; G Gutierrez-Silerio; A Sobrevilla-Navarro; B Bastidas-Ramírez; L Hernández-Ortega; C Gurrola-Díaz; L Gasca-Lozano; J Armendáriz-Borunda; A Salazar-Montes
Journal:  Mol Biotechnol       Date:  2021-10-22       Impact factor: 2.695

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.